Notis McConarty Edward Sells 1,200 Shares of Roche Holdings AG Basel ADR (OTCMKTS:RHHBY)

Notis McConarty Edward lessened its stake in Roche Holdings AG Basel ADR (OTCMKTS:RHHBY) by 3.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 37,450 shares of the company’s stock after selling 1,200 shares during the quarter. Notis McConarty Edward’s holdings in Roche Holdings AG Basel were worth $1,364,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of RHHBY. Douglass Winthrop Advisors LLC raised its holdings in Roche Holdings AG Basel by 9.2% during the 2nd quarter. Douglass Winthrop Advisors LLC now owns 637,978 shares of the company’s stock valued at $22,393,000 after acquiring an additional 53,702 shares during the period. Scout Investments Inc. raised its holdings in Roche Holdings AG Basel by 15.9% during the 2nd quarter. Scout Investments Inc. now owns 103,699 shares of the company’s stock valued at $3,651,000 after acquiring an additional 14,204 shares during the period. Boston Private Wealth LLC raised its holdings in Roche Holdings AG Basel by 46.6% during the 2nd quarter. Boston Private Wealth LLC now owns 10,240 shares of the company’s stock valued at $361,000 after acquiring an additional 3,254 shares during the period. Diversified Trust Co raised its holdings in Roche Holdings AG Basel by 1.2% during the 2nd quarter. Diversified Trust Co now owns 48,764 shares of the company’s stock valued at $1,717,000 after acquiring an additional 599 shares during the period. Finally, Sky Investment Group LLC raised its holdings in Roche Holdings AG Basel by 0.7% during the 2nd quarter. Sky Investment Group LLC now owns 63,466 shares of the company’s stock valued at $2,228,000 after acquiring an additional 445 shares during the period. 0.32% of the stock is currently owned by institutional investors and hedge funds.

A number of equities research analysts have issued reports on the stock. ValuEngine cut shares of Roche Holdings AG Basel from a “hold” rating to a “sell” rating in a report on Tuesday, September 10th. UBS Group raised shares of Roche Holdings AG Basel from a “neutral” rating to a “buy” rating in a report on Friday, July 26th. One analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $37.00.

RHHBY stock traded up $0.23 during midday trading on Friday, reaching $37.39. 602,461 shares of the company’s stock traded hands, compared to its average volume of 1,246,449. The company has a 50-day moving average price of $36.49 and a two-hundred day moving average price of $34.63. Roche Holdings AG Basel ADR has a 52 week low of $29.45 and a 52 week high of $37.79. The firm has a market capitalization of $253.39 billion, a PE ratio of 16.12, a price-to-earnings-growth ratio of 2.32 and a beta of 0.50.

Roche Holdings AG Basel Company Profile

Roche Holding AG engages in the diagnostics and prescription pharmaceuticals businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anaemia, anticoagulation therapy, bone, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid and liver disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus and infectious diseases.

Featured Story: How to find the components of the quick ratio

Institutional Ownership by Quarter for Roche Holdings AG Basel (OTCMKTS:RHHBY)

Receive News & Ratings for Roche Holdings AG Basel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holdings AG Basel and related companies with MarketBeat.com's FREE daily email newsletter.